.

BioPharmaceutical Business Intelligence

  • Analyze global market entry opportunities
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Federal Trade Commission
US Army
Chinese Patent Office
Fish and Richardson
QuintilesIMS
Teva
AstraZeneca
Queensland Health
Fuji
Novartis

Generated: September 23, 2017

DrugPatentWatch Database Preview

Details for Patent: ► Subscribe

« Back to Dashboard

Details for Patent: ► Subscribe

Title:Methods for controlled release oral dosage of a vitamin D compound
Abstract: A stable, controlled release formulation for oral dosing of vitamin D compounds is disclosed. The formulation is prepared by incorporating one or more vitamin D compounds into a solid or semi-solid mixture of waxy materials. Oral dosage forms can be prepared by melt-blending the components described herein and filling gelatin capsules with the formulation.
Inventor(s): Bishop; Charles W. (Mount Horeb, WI), Tabash; Samir P. (Whitby, CA), Agudoawu; Sammy Asiamah (Mississauga, CA), White; Jay A. (Newmarket, CA), Crawford; Keith H. (Highlands Ranch, CO), Messner; Eric J. (Lake Forest, IL), Petkovich; P. Martin (Kingston, CA)
Assignee: Opko IP Holdings II, Inc. (Grand Cayman, KY) Opko Renal, LLC (Miami, FL)
Filing Date:Jan 22, 2013
Application Number:13/746,982
Claims:1. A method of administering an amount of a vitamin D compound to a patient by controlled release such that (a) the ratio of the maximum serum concentration within 24 hours after administration of the vitamin D compound to the concentration 24 hours after administration (Cmax.sub.24hr/C.sub.24hr) is reduced as compared to an equivalent amount of the vitamin D compound administered by bolus IV injection and/or an immediate-release, oral dosage form and/or (b) the time for the plasma concentration of the vitamin D compound to reach its maximum in a dose interval following administration (Tmax) is increased as compared to Tmax for an equivalent amount of the vitamin D compound administered by bolus IV injection and/or an equivalent immediate-release, oral dosage form, wherein the vitamin D compound comprises 25-hydroxyvitamin D.sub.3.

2. The method according to claim 1, wherein (a) the ratio of the maximum serum concentration within 24 hours after administration of the vitamin D compound to the concentration 24 hours after administration (Cmax.sub.24hr/C.sub.24hr) is reduced as compared to an equivalent amount of the vitamin D compound administered by bolus IV injection and/or an immediate-release, oral dosage form.

3. The method according to claim 1, comprising administering 25-hydroxyvitamin D.sub.3 to a human patient in an amount in a range of 1 to 100 .mu.g per day for an extended period of time.

4. The method of claim 3, wherein the extended period of time is at least one month.

5. The method according to claim 2, wherein the human patient is vitamin D deficient.

6. The method according to claim 2, wherein the human patient is vitamin D replete.

7. The method according to claim 2, wherein the human patient has secondary hyperparathyroidism associated with vitamin D deficiency.

8. The method according to claim 7, comprising administering 25-hydroxyvitamin D.sub.3 to the human patient to lower elevated PTH in a human patient by raising the patient's serum concentration of 25(OH)D to at least 30 ng/mL.

9. The method of claim 2, wherein the reduction in the ratio of the maximum serum concentration within 24 hours after administration of the vitamin D compound to the concentration 24 hours after administration (Cmax.sub.24hr/C.sub.24hr) is by a factor of at least 20%.

10. The method of claim 1, wherein (b) the time for the plasma concentration of the vitamin D compound to reach its maximum in a dose interval following administration (Tmax) is increased as compared to Tmax for an equivalent amount of the vitamin D compound administered by bolus IV injection and/or an equivalent immediate-release, oral dosage form.

11. The method according to claim 10, comprising administering 25-hydroxyvitamin D.sub.3 to a human patient in an amount in a range of 1 to 100 .mu.g per day for an extended period of time.

12. The method of claim 11, wherein the extended period of time is at least one month.

13. The method according to claim 10, wherein the human patient is vitamin D deficient.

14. The method according to claim 10, wherein the human patient is vitamin D replete.

15. The method according to claim 10, wherein the human patient has secondary hyperparathyroidism associated with vitamin D deficiency.

16. The method according to claim 15, comprising administering 25-hydroxyvitamin D.sub.3 to the human patient to lower elevated PTH in a human patient by raising the patient's serum concentration of 25(OH)D to at least 30 ng/mL.

17. The method according to claim 10, wherein the increase in the time for the plasma concentration of the vitamin D compound to reach its maximum in a dose interval following administration (Tmax) is by a factor of at least 25%.

18. The method of claim 1, comprising administering 25-hydroxyvitamin D.sub.3 to a human patient to prevent the patient's serum concentration of 25(OH)D from falling below 30 ng/mL.

19. The method according to claim 2, comprising administering 25-hydroxyvitamin D.sub.3 to a human patient in an amount in a range of 1 to 100 .mu.g per day for an extended period of time.

20. The method of claim 19, wherein the extended period of time is at least one month.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

US Army
Cerilliant
Fish and Richardson
Covington
McKesson
Dow
Harvard Business School
Colorcon
Queensland Health
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot